ICG Enterprise Trust plc (the “Company”)

11 September 2026

Transaction in Own Shares

The Company announces that on 10 September 2026 it bought back 10,000 of its own shares under the long-term buyback programme, to be held as treasury shares, at an average price of 1431 pence per share.

Further details are set out below:

  • Number of shares held as treasury shares following settlement of this purchase: 3,144,402
  • Total shares in issue excluding treasury shares following settlement of this purchase: 60,409,790

The Company has bought back these shares under the authority granted by shareholders at its Annual General Meeting in June 2026, which permits the Company to repurchase a maximum of 14.99% of its ordinary shares. The actual number of shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2027), or until expressly revoked by shareholders.

No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company’s current intention to hold any shares bought back in treasury.

The Company has instructed Numis Securities Limited (trading for these purposes as Deutsche Numis) as its broker in respect of its buyback transactions. This arrangement is in accordance with the UKLA Listing Rules and the Company’s general authority to repurchase shares.

Analyst / Investor enquiries:

Chris Hunt
Shareholder Relations, ICG
+44 (0) 20 3545 2020

Andrew Lewis
Company Secretary, ICG
+44 (0) 20 3545 1344

Media:

Clare Glynn
Corporate Communications, ICG
+44 (0) 20 3545 1395

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Transaction in Own Shares

St Peter Port, Guernsey 11 September 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 11 June 2026 and the share buy-back agreement with Jefferies International Limited.

Transaction on London Stock Exchange

Date of purchase of Shares

10 September 2026
Number of Shares purchased

50,000 Class A Shares
Highest price/lowest price paid

£14.70 / £14.70
ISIN for the Shares GG00B1ZBD492

All Class A Shares bought back will be cancelled. Following the cancellation, the number of outstanding Class A Shares is 38,941,702‬. The Company also has 3,150,408 Class A shares held in treasury. For reporting purposes under the FCA’s Disclosure Guidance and Transparency Rules the market should use the figure of 38,941,702 voting rights when determining if they are required to notify their interest in, or a change to their interest in the Company.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Oak Group        +44 1481 723450

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

NBPE invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger
Neuberger is an employee-owned, private, independent investment manager founded in 1939 with approximately 3,000 employees across 26 countries. The firm manages $567 billion of equities, fixed income, private markets, real estate and hedge fund portfolios for global institutions, advisors and individuals. Neuberger’s investment philosophy is founded on active management, fundamental research and engaged ownership. The firm is proud to be recognized for its commitment to its two constituents, clients and employees. Again this past year, we were named Best Asset Manager for Institutional Investors in the US (Crisil Coalition Greenwich) and the #1 Best Place to Work in Money Management (Pensions & Investments, firms with more than 1,000 employees). Neuberger has no corporate parent or unaffiliated external shareholders. Visit www.nb.com for more information, including www.nb.com/disclosure-global-communications for information on awards.
Data as of March 31, 2026.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

All Neuberger figures are as of March 31, 2026, unless otherwise noted, and are subject to change without notice. The firm data, including employees and assets under management, reflect the collective data of the various affiliated investment advisors who are subsidiaries of Neuberger Berman Group LLC. The company history/timeline includes the history of all the company’s subsidiaries, including predecessor companies and acquisitions.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

This press release appears as a matter of record only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.

NBPE is established as a closed-end investment company domiciled in Guernsey. NBPE has received the necessary consent of the Guernsey Financial Services Commission. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. This document is not intended to constitute legal, tax or accounting advice or investment recommendations. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Statements contained in this document that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of NBPE’s investment manager. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this document contains “forward-looking statements.” Actual events or results or the actual performance of NBPE may differ materially from those reflected or contemplated in such targets or forward-looking statements.

Octopus Titan VCT plc

Net Asset Value

The Board of Octopus Titan VCT plc (the “Company”) has reviewed the portfolio and announces that, as at 30 June 2026, the unaudited Net Asset Value (“NAV”) of the Company was 45.1 pence per share, representing an increase of approximately 1.3% from 44.5 pence per share as at 31 December 2025.

The increase reflects a combination of positive valuation movements across parts of the portfolio, including from companies demonstrating strong underlying performance, and gains realised on disposals during the period. These were partly offset by valuation reductions elsewhere in the portfolio, including the impact of continued pressure on comparable market multiples.

Further details will be provided in the half-year report due to be released later in September 2026.

For further information please contact:

Rachel Peat
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800A67IKGG6PVYW75

BPCE S.A.
Legal Entity Identifier (LEI): 9695005MSX1OYEMGDF46

Société anonyme à directoire et conseil de surveillance

Share capital: €242 487 090

Registered office: 7, promenade Germaine Sablon, 75013 Paris, France

RCS Paris 493 455 042

(the « Issuer »)

NOTICE OF EARLY REDEMPTION TO THE NOTEHOLDERS

dated 11 September 2026

in relation to the

BPCE €900,000,000 Contingent Tier 2 Capital Subordinated Fixed Rate Resettable Notes due January 2042 issued as Series no.: 2021-13

(ISIN: FR0014005V34) (the “Notes”)

On 13 October 2021, the Issuer issued the Notes with a prospectus dated 11 October 2021 which received approval no. 21-438 from the Autorité des marchés financiers (the “Prospectus”), which includes the terms and conditions of the Notes (the “Conditions”). Capitalized terms not specifically defined in this notice shall have the meaning given to them in the Conditions.

Notice is hereby given that, pursuant to Condition 7.2 (Redemption at the option of the Issuer) of the Conditions, the Issuer will redeem the Notes in full on 13 October 2026 (the “Optional Redemption Date” ).

An Euronext Paris notice regarding the delisting of the Notes will be published, with effect on such date accordingly.

At the Optional Redemption Date, the Issuer will pay to each noteholder the principal amount of such Notes together with any interest accrued up to (but excluding) the Optional Redemption Date (the “Optional Redemption Amount”).

Fiscal Agent, Principal Paying Agent and Calculation Agent:

BNP PARIBAS (acting through its Securities Services business)

Les Grands Moulins de Pantin

9, rue du Débarcadère

93500 Pantin

France

By: BPCE

Attachment

Press Release
Nicox Announces NCX 470 NDA in China Accepted for Review
  • Acceptance of the NCX 470 dossier initiates the review process
  • Regulatory decision expected within 12-18 months from the August submission
  • Q&A on Ocumension available on Nicox’s website

September 11, 2026 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive licensee in China, Ocumension Therapeutics, has received confirmation from China’s National Medical Products Administration (NMPA) that the NCX 470 (also referred to as OT-301 by Ocumension) New Drug Application (NDA) in China has been accepted for review. This acceptance initiates the review of the NDA by the NMPA. Nicox had previously announced the submission of the NCX 470 NDA in China as a treatment to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

“The acceptance for review of the NCX 470 NDA in China initiates the examination process and is another key step towards its commercialisation in this territory. We look forward to continuing to work with the Ocumension team as they prepare for a future launch.” said Gavin Spencer, Chief Executive Officer of Nicox.

Ocumension’s Press release is here.

Ocumension has paid Nicox license fees of €18 million for the rights to develop and commercialise NCX 470 in the Chinese, Korean and Southeast Asian markets, contributed 50% of the Denali clinical trial costs and is one of Nicox’s principal shareholders. Nicox will receive tiered royalties on sales of NCX 470 made by Ocumension ranging from 6% to 12%. Ocumension already has an ophthalmology sales force in place throughout China and is therefore well-positioned for a rapid launch of NCX 470.

There is no fixed period for approval of a pharmaceutical product in China, however the review process typically takes 12 to 18 months following submission. The decision on NCX 470 in China is expected after the decision by the U.S. FDA, who have assigned the PDUFA date1 for 30 April 2027.  

Key Upcoming NCX 470 Milestones

  • Japan Phase 3 clinical trials results: trials ongoing  
  • NDA approval in the U.S.: PDUFA date 30 April 2027
  • U.S. Launch: expected in H2 2027, subject to NDA approval
  • NDA decision in China: Submission made in August 2026, accepted for review on 10 September 2026
About NCX 470
NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signalling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs.

NCX 470 has completed two Phase 3 clinical trials designed to fulfil the regulatory requirements for safety and efficacy to support NDA submissions in the U.S. and China, Mont Blanc and Denali. Both trials were positive and met the efficacy endpoints necessary for submission of a New Drug Application in the United States and China. NDAs for NCX 470 have been submitted in the U.S. and China. NCX 470 is an investigational product and has not yet been approved by the FDA.

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world.  Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX).

For more information www.nicox.com

Analyst coverage
H.C. Wainwright & Co        Yi Chen           New York, U.S.  
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts  
Nicox
Gavin Spencer
Chief Executive Officer
T +33 (0)4 97 24 53 00
communications@nicox.com
 
Disclaimer
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2025” which are available on Nicox’s website (www.nicox.com).

Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.

Nicox S.A.
Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France
T +33 (0)4 97 24 53 00


1 A PDUFA date is the target date by which the U.S. Food and Drug Administration (FDA) aims to complete its review and issue a decision on a New Drug Application (NDA) under the Prescription Drug User Fee Act (PDUFA).

Attachment

Lille (France), Cambridge (Massachusetts, United States), September 11, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit GENFIT to the CAC Mid 60 and SBF 120 indices.

These changes will become effective after the market closes on Friday, September 18, 2026.

Pascal Prigent, CEO of GENFIT, commented: “We are pleased to be added to the Euronext CAC Mid 60 and SBF 120 indices. This inclusion comes after a positive momentum for GENFIT and growing investor confidence in our strategy and our ability to execute on it. This milestone further validates our continued commitment to bringing innovative therapies and diagnostic solutions to patients with rare and life-threatening liver diseases while creating long-term value for our shareholders.”

The CAC Mid 60 and SBF 120 are among the most widely-followed indices on Euronext Paris, representing mid-sized listed companies and a broader selection of 120 major securities, respectively. The company’s admission to the SBF 120 reflects its increased market capitalization, liquidity and visibility. It is expected to enhance the company’s profile among institutional investors and confirms its growing relevance within the French equity market.

END

ABOUT GENFIT

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT’s expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.1   Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT’s largest shareholders, acquiring an 8% stake in the Company’s capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements regarding the expected benefits of GENFIT’s inclusion in the CAC Mid 60 and SBF 120 indices, investor interest in the Company, the Company’s strategic positioning, its ability to execute on its strategy, its future growth prospects, the advancement of its pipeline and the creation of long-term value for shareholders. The use of certain words, such as “believe”, “potential”, “expect”, “target”, “may”, “will”, “should”, “could”, “if” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Inclusion in stock market indices does not guarantee increased liquidity, sustained investor interest, share price appreciation or future operating performance. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Risk Factors and Internal Control” of the Company’s 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers (“AMF”), which is available on GENFIT’s website (www.genfit.fr) and the AMF’s website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACTS

GENFIT | Investors

Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 |
jean-christophe.marcoux@genfit.com

Kevin Gardner – Life Science Advisors | kgardner@lifesciadvisors.com

GENFIT | Media

Bruno ARABIAN – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.fr

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com 


1 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo®

Attachment

NOTICE

Elis announces the early redemption on 13 October 2026 of its €380,000,000 2.25% bonds convertible into new shares and/or exchangeable for existing shares
due 2029 (OCEANEs)
ISIN FR001400AFJ9 (the “Bonds”)

Puteaux, September 11, 2026 – Elis (the “Company”) informs the holders of the Bonds (the “Bondholders”) that it will proceed with the early redemption on 13 October 2026 (the “Early Redemption Date”) of all Bonds outstanding on such date, pursuant to the first paragraph of Condition 1.10.1.3, “Early redemption at the Company’s option”, of the terms and conditions of the Bonds dated 22 September 2022 (the “Terms and Conditions”).

Capitalised terms that are not otherwise defined in this notice shall have the meanings given to them in the Terms and Conditions.

Unless the Bondholders exercise their Conversion/Exchange Right in accordance with the Terms and Conditions, the Company will redeem in cash on the Early Redemption Date each Bond outstanding on such date at a price per Bond equal to EUR 100,129.45 (the “Early Redemption Price”), being the par value of each Bond (EUR 100,000) together with EUR 129.45 in accrued interest calculated from (and including) 22 September 2026 to (but excluding) the Early Redemption Date.

In accordance with the first paragraph of Condition 1.10.1.3 of the Terms and Conditions, at the Company’s request, Conv-Ex Advisors Limited, acting as Calculation Agent in respect of the Bonds, has verified that the arithmetic mean, calculated over a period of 20 consecutive Trading Days from (and including) 11 August 2026 to (and including) 7 September 2026, selected by the Company from among the 40 consecutive Trading Days from (and including) 17 July 2026 to (and including) 10 September 2026, of the products, in respect of each such Trading Day, of (i) the Volume-Weighted Average Price of the Shares on that Trading Day and (ii) the Conversion/Exchange Ratio applicable on that Trading Day, exceeded 130% of the par value of each Bond.

In accordance with Conditions 1.10.1.3 and 2.3 of the Terms and Conditions, a Bondholder may exercise its Conversion/Exchange Right in respect of any Bond held by it, provided that the relevant Request Date in respect of such exercise falls no later than 2 October 2026 (being the seventh (7th) Business Day preceding the Early Redemption Date), and that such exercise is otherwise made in accordance with the Terms and Conditions.

Bondholders wishing to exercise their Conversion/Exchange Right should contact the financial intermediary holding their Bonds in a securities account sufficiently in advance so that all requirements for a valid exercise, including receipt of the exercise request and transfer of the corresponding Bonds, are completed by the applicable deadline. The centralising agent for the Bonds is Uptevia, Cœur Défense Tour A – 90-110 Esplanade du Général de Gaulle 92400 Courbevoie (the “Centralising Agent”).

Each Bond in respect of which the Conversion/Exchange Right has not been validly exercised by the applicable deadline will be redeemed in cash at the Early Redemption Price on the Early Redemption Date.

As of the date of this notice, 3,800 Bonds remain outstanding out of a total of 3,800 Bonds initially issued. The Conversion/Exchange Ratio is currently equal to 6,256.8564 Shares per Bond. Assuming that all Bondholders exercise their Conversion/Exchange Right, a maximum of 23,776,054 Elis shares could be delivered, representing approximately 10.21% of the Company’s current share capital, subject to any subsequent adjustment of the Conversion/Exchange Ratio in accordance with the Terms and Conditions. The Company intends to use the existing Shares it holds following the completion of its share buyback program on 9 July 2026, thereby limiting the number of newly issued Shares that may be required. Bondholders validly exercising their Conversion/Exchange Right may receive newly issued Shares and/or existing Shares, as determined by the Company. Settlement and delivery of Shares will occur in accordance with the Terms and Conditions and the instructions of the Centralising Agent.

IMPORTANT NOTICE

The early redemption of the Bonds may not be accepted in any jurisdiction where such redemption would be prohibited or restricted by applicable law, or by residents of any such jurisdiction. No document relating to the exercise of the early redemption option may be transmitted, directly or indirectly, in or into any such jurisdiction or to any such person.

This notice does not constitute an offer to sell, a solicitation of an offer to purchase, or an offer to purchase any securities of Elis in any jurisdiction.

Contacts

Nicolas Buron
Director of Investor Relations, Financing & Treasury
Phone: + 33 (0)1 75 49 98 30 – nicolas.buron@elis.com

Charline Lefaucheux
Investor Relations
Phone: + 33 (0)1 75 49 98 15 – charline.lefaucheux@elis.com

Attachment

Ageas completes the sale of its 30.95% stake in Maybank Ageas Holdings Berhad to Maybank

Ageas announces today the completion of the sale of its 30.95% stake in the share capital of Maybank Ageas Holdings Berhad (MAHB) to Maybank for a total cash consideration equivalent to EUR 1.1 billion1.

The transaction generates a net capital gain after tax of EUR 464 million. The agreement values 100% of MAHB at EUR 3.5 billion, implying a price-to-book (P/B) ratio of about 2x the 2025 IFRS Equity.

The completion of the transaction allows Ageas to realise the significant value created through its more than 25-year partnership with Maybank. The transaction further demonstrates the value-creating potential of Ageas’s partnership model and enhances the Group’s financial flexibility.

The transaction is solvency accretive, adding 23pp to the Solvency II ratio. 

Ageas sincerely thanks Maybank’s management and all Etiqa employees for their collaboration throughout our partnership and wishes the company continued success in the years ahead. 

Ageas is a Belgian rooted listed international insurance Group with a heritage spanning 200 years. It offers Retail and Business customers Life and Non-Life insurance products designed to suit their specific needs, today and tomorrow, and is also engaged in reinsurance activities. As one of Europe’s larger insurance companies, Ageas concentrates its activities in Europe and Asia, which together make up the major part of the global insurance market. It operates successful insurance businesses in Belgium, the UK, Portugal, Türkiye, China, India, Thailand, Vietnam, Laos, Cambodia and the Philippines through a combination of wholly owned subsidiaries and long-term partnerships with strong financial institutions and key distributors. Ageas ranks among the market leaders in the countries in which it operates. It represents a staff force of about 53,000 people and reported annual inflows of EUR 19.6 billion in 2025.


1 Including a EUR 53 million pre-completion dividend.

Attachment

AUCKLAND, New Zealand, Sept. 11, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB), a global leader in launch services and space systems, today launched its 16th Electron rocket of the year with a dedicated mission for a confidential customer.

The “Happily Ever Faster” mission lifted off from Rocket Lab Launch Complex 1 in New Zealand at 3:28 p.m. NZST on 11 September and successfully deployed a single Earth observation satellite to a 500km circular low Earth orbit.

“Happily Ever Faster” is Rocket Lab’s 16th launch of the year and 95th launch overall. Rocket Lab’s next Electron launch is scheduled to take place from Launch Complex 1 for another commercial constellation operator before the end of the month. As global launch availability continues to strain the market, Electron’s regular and reliable launch cadence provides schedule certainty and dedicated access to space for satellite operators of the industry’s next-generation constellations.

Rocket Lab Media Contact
Murielle Baker
media@rocketlabusa.com

About Rocket Lab
Rocket Lab (Nasdaq: RKLB) is an end-to-end space company delivering rockets, satellites, and spacecraft components for commercial, government, and defense missions. Driven by its industry-leading small-lift rockets Electron and HASTE and its upcoming reusable Neutron medium-lift rocket, Rocket Lab delivers reliable and responsive launch for the world’s most important missions from constellation deployment to missile defense. Rocket Lab’s satellites and components have powered more than 1,700 missions in Earth orbit, as well as deep-space exploration of the Moon, Mars, and beyond. Learn more at www.rocketlabcorp.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “strategy,” “future,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of our website at https://investors.rocketlabcorp.com which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

COLUMBIA, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) — Tenable Holdings, Inc. (Nasdaq: TENB) (“Tenable”), the exposure management company, announced today the pricing of $725.0 million aggregate principal amount of 0.25% Convertible Senior Notes due 2031 (the “notes”) in a private placement (the “offering”) only to persons reasonably believed to be “qualified institutional buyers” pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $650.0 million aggregate principal amount of the notes. Tenable has also granted the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $75.0 million aggregate principal amount of the notes. The sale of the notes to the initial purchasers is expected to close on September 15, 2026, subject to customary closing conditions.

The notes will be general senior unsecured obligations of Tenable. The notes will accrue interest payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2027, at a rate of 0.25% per year. The notes will mature on September 15, 2031, unless earlier converted, redeemed or repurchased.

Tenable estimates that the net proceeds from the offering will be approximately $705.6 million (or approximately $778.8 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers’ discounts and estimated offering expenses. Tenable expects to use the net proceeds from the offering (i) to pay the approximately $58.1 million cost of the capped call transactions described below, (ii) to repurchase approximately $170.5 million of its common stock concurrently with the pricing of the notes as described below, (iii) to pay the cost of repaying in full the term loans under Tenable’s senior secured credit facility (the “credit facility”) and (iv) for general corporate purposes, which may include additional share repurchases, acquisitions or strategic investments in complementary businesses or technologies, working capital, operating expenses, capital expenditures and general and administrative expenses. If the initial purchasers exercise their option to purchase additional notes, Tenable expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions, with the remainder to be used for general corporate purposes.

The notes will be convertible at the option of the holders in certain circumstances. Upon conversion, Tenable will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, shares of Tenable’s common stock or a combination of cash and shares of Tenable’s common stock, at Tenable’s election, in respect of the remainder, if any, of Tenable’s conversion obligation in excess of the aggregate principal amount of the notes being converted.

The conversion rate will initially be 22.3005 shares of Tenable’s common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $44.84 per share of Tenable’s common stock). The initial conversion price represents a premium of approximately 40.0% over the last reported sale price of $32.03 per share of Tenable’s common stock on September 10, 2026. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or if Tenable delivers a notice of redemption, it will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with such a corporate event or convert its notes called (or deemed called, in the case of an optional redemption) for redemption during the related redemption period, as the case may be.

Tenable may not redeem the notes prior to September 20, 2029, except in the event of a cleanup redemption described below. Tenable may redeem for cash all or any portion of the notes (subject to certain limitations), at its option, on a redemption date on or after September 20, 2029 and before the 31st scheduled trading day immediately prior to the maturity date if the last reported sale price of Tenable’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which Tenable provides the related notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. In addition, subject to certain conditions, Tenable may redeem for cash all, but not less than all, of the notes at any time before the 31st scheduled trading day immediately prior to the maturity date if the aggregate principal amount of the notes that remains outstanding at such time is less than $80.0 million at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

If Tenable undergoes a “fundamental change” (as defined in the indenture that will govern the notes) then, subject to certain conditions and exceptions, holders may require Tenable to repurchase for cash all or any portion of their notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

In connection with the pricing of the notes, Tenable entered into privately negotiated capped call transactions with certain of the initial purchasers or affiliates thereof and certain other financial institutions (the “option counterparties”). The capped call transactions cover, subject to customary adjustments substantially similar to those applicable to the notes, the number of shares of Tenable’s common stock initially underlying the notes. The capped call transactions are expected generally to reduce the potential dilution to Tenable’s common stock upon any conversion of notes and/or offset any cash payments Tenable is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. If the initial purchasers exercise their option to purchase additional notes, Tenable expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions with the option counterparties.

The cap price of the capped call transactions relating to the notes will initially be $64.06, which represents a premium of 100.0% over the last reported sale price of Tenable’s common stock on the Nasdaq Global Select Market on September 10, 2026, and is subject to certain adjustments under the terms of the capped call transactions.

In connection with establishing their initial hedges of the capped call transactions, Tenable expects that the option counterparties or their respective affiliates will purchase shares of Tenable’s common stock and/or enter into various derivative transactions with respect to Tenable’s common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Tenable’s common stock or the notes at that time.

In addition, Tenable expects that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Tenable’s common stock and/or purchasing or selling Tenable’s common stock or other securities of Tenable in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of notes, following any redemption of the notes or any repurchase of the notes upon a fundamental change, or, to the extent Tenable exercises the relevant election under the capped call transactions, following any other repurchase of the notes). This activity could also cause or avoid an increase or a decrease in the market price of Tenable’s common stock or the notes, which could affect the ability of a holder of notes to convert the notes and, to the extent the activity occurs during any observation period related to a conversion of notes, it could affect the number of shares, if any, and value of the consideration that a holder of notes will receive upon conversion of the notes.

Tenable expects to use approximately $170.5 million of the net proceeds from the offering to repurchase approximately 5.3 million shares of its common stock concurrently with the pricing of the notes in privately negotiated transactions effected with or through one of the initial purchasers of the notes or its affiliate at a purchase price per share equal to the last reported sale price of Tenable’s common stock on the Nasdaq Global Select Market on September 10, 2026. These repurchases could increase (or reduce the size of any decrease in) the market price of Tenable’s common stock or the notes prior to, concurrently with or shortly after the pricing of the notes and could have resulted in a higher effective conversion price for the notes. Tenable may also conduct further repurchases of its common stock after the offering is completed pursuant to its previously authorized share repurchase program.

The notes were only offered to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A promulgated under the Securities Act by means of a private offering memorandum. The notes and any shares of Tenable’s common stock issuable upon conversion of the notes have not been and will not be registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.

This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.

About Tenable

Tenable is the exposure management company, exposing and closing the cybersecurity gaps that erode business value, reputation and trust. Tenable’s AI-powered exposure management platform radically unifies security visibility, insight and action across the attack surface, equipping modern organizations to protect against attacks from IT infrastructure to cloud environments to critical infrastructure and everywhere in between. By protecting enterprises from security exposure, Tenable reduces business risk for over 40,000 customers around the globe.

Forward-Looking Statements

This press release contains “forward-looking” statements, as that term is defined under the federal securities laws, including statements concerning the proposed terms of the notes and capped call transactions, the completion, timing and size of the proposed offering of the notes and capped call transactions, the anticipated use of proceeds from the offering, including the repayment of the term loans under the credit facility and Tenable’s plan to repurchase shares of outstanding common stock and the terms of any repurchase transactions, the potential impact of the foregoing or related transactions on dilution to holders of Tenable’s common stock, the market price of Tenable’s common stock or the notes or the conversion price of the notes. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Tenable’s control. Tenable’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to whether Tenable will consummate the offering of notes on the expected terms or at all, which could differ or change based upon market conditions or for other reasons, and the other risks detailed in Tenable’s Form 10-K filed with the Securities and Exchange Commission (“SEC”) for the year ended December 31, 2025, in Tenable’s quarterly reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026 and in other filings and reports that Tenable may file from time to time with the SEC. The forward-looking statements included in this press release represent Tenable’s views as of the date of this press release. Tenable anticipates that subsequent events and developments will cause Tenable’s views to change. Tenable undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tenable’s views as of any date subsequent to the date of this press release.

Media Contact
Tenable
tenablepr@tenable.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.